0001140361-23-015527.txt : 20230331 0001140361-23-015527.hdr.sgml : 20230331 20230331213152 ACCESSION NUMBER: 0001140361-23-015527 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230329 FILED AS OF DATE: 20230331 DATE AS OF CHANGE: 20230331 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Malecek Michael J CENTRAL INDEX KEY: 0001779336 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35676 FILM NUMBER: 23790178 MAIL ADDRESS: STREET 1: C/O PROTHENA BIOSCIENCES, INC. STREET 2: 331 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PROTHENA CORP PUBLIC LTD CO CENTRAL INDEX KEY: 0001559053 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 77 SIR JOHN ROGERSON'S QUAY, BLOCK C STREET 2: GRAND CANAL DOCKLANDS CITY: DUBLIN 2 STATE: L2 ZIP: D02 VK60 BUSINESS PHONE: 011-353-1-236-2500 MAIL ADDRESS: STREET 1: 77 SIR JOHN ROGERSON'S QUAY, BLOCK C STREET 2: GRAND CANAL DOCKLANDS CITY: DUBLIN 2 STATE: L2 ZIP: D02 VK60 FORMER COMPANY: FORMER CONFORMED NAME: Prothena Corp plc DATE OF NAME CHANGE: 20121102 FORMER COMPANY: FORMER CONFORMED NAME: Neotope Corp Ltd DATE OF NAME CHANGE: 20120926 4 1 form4.xml X0407 4 2023-03-29 0001559053 PROTHENA CORP PUBLIC LTD CO PRTA 0001779336 Malecek Michael J C/O PROTHENA BIOSCIENCES INC 331 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 true Chief Legal Officer true Ordinary Shares, par value $0.01 per share 2023-03-29 4 M 0 5000 10.27 A 5000 D Ordinary Shares, par value $0.01 per share 2023-03-29 4 S 0 2734 48.8135 D 2266 D Ordinary Shares, par value $0.01 per share 2023-03-29 4 S 0 2266 49.2794 D 0 D Stock Option (Right to Buy) 10.27 2023-03-29 4 M 0 5000 0 D 2029-07-01 Ordinary Shares 5000 120000 D The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 20, 2022. The transaction was executed in multiple trades in prices ranging from $48.02 to $49.00, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 3 of this Form 4. The transaction was executed in multiple trades in prices ranging from $49.05 to $49.505, inclusive. The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on July 1, 2020, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. /s/ Michael J. Malecek 2023-03-31